Skip to Content

Dactinomycin use while Breastfeeding

Drugs containing Dactinomycin: Cosmegen

Medically reviewed by Drugs.com. Last updated on March 8, 2021.

Dactinomycin Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of dactinomycin during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. The manufacturer recommends that breastfeeding be discontinued during dactinomycin therapy and for 14 days after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Dactinomycin

CAS Registry Number

50-76-0

Drug Class

  • Breast Feeding
  • Lactation
  • Antineoplastic Agents
  • Antibiotics, Antineoplastic
  • Protein Synthesis Inhibitors
  • Nucleic Acid Synthesis Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.